Perfectha Derm 1x 1,0 ml

Perfectha Derm contains 20 mg/mL of non-animal, cross-linked hyaluronic acid formulated with E-BRID technology, creating 90,000 gel particles per mL for a balanced lift-to-flow ratio. Covalent bonds both within and between the particles minimise free BDDE to undetectable levels, reducing potential inflammatory reactions compared with older biphasic fillers.

E-BRID’s monodensified network distributes mechanical stress evenly, allowing the gel to mould into dermal micro-pockets without clumping. In practice, clinicians report smoother palpation versus similarly concentrated gels that rely on high G’ alone. Laboratory rheology shows an elastic modulus just over 120 Pa—enough to resist musculo-cutaneous shear yet soft enough for perioral use.

Because the HA is sourced by bacterial fermentation, allergy testing is unnecessary, and the product remains fully reversible with hyaluronidase if over-correction occurs. The 1 mL presentation allows precise metering; typical mid-face sessions require 0.5–1 mL, limiting needle passes and downtime.

Finally, Perfectha’s CE Class III designation mandates batch sterility testing and endotoxin limits below 0.5 EU/mL—standards verified during each production run at Sinclair’s FDA-inspected facility in France.

Perfectha Derm targets the mid-dermis, bridging the gap between superficial line fillers and deep volumisers. Ideal candidates present with moderate nasolabial folds, marionette lines, glabellar furrows or mild lip atrophy. In a 60-patient observational study, 94% of injections achieved a ≥1-grade improvement on the Wrinkle Severity Rating Scale at day 30, with sustained correction in 82% at month 9.

Compared with calcium-hydroxyapatite or PLLA biostimulators, Perfectha offers immediate contour, lower nodule risk and straightforward dissolution—advantages for patients seeking predictable, reversible outcomes. Against rival HA gels such as Juvederm Ultra, the E-BRID matrix provides equivalent projection using 15–20% less product, according to split-face ultrasound volumetry.

The filler also performs well in dynamic zones: its particle distribution dampens shear forces, reducing visibility when smiling or speaking. Off-label, practitioners employ micro-aliquots for philtral column support and chin tip refinement; however, intranasal use is discouraged due to vascular compromise risk.

Every Perfectha Derm retail unit arrives in a tamper-evident blister containing:

1 × 1 mL sterile glass syringe (Luer-Lock) pre-filled with 20 mg/mL HA gel

2 × 30 G ½″ sterile needles for linear threading or depot placement

1 multilingual package insert outlining indications, contraindications and emergency hyaluronidase protocol

2 peel-off traceability labels carrying batch, lot and UDI codes for the patient record

Sinclair’s packaging maintains a validated 2–25 °C cold chain; viscosity shift remains under 5% after three freeze–thaw cycles, but the manufacturer advises single-use disposal within four hours of opening.

Clinical and real-world data place Perfectha Derm’s longevity between six and twelve months, with patient metabolism and injection depth as key modifiers. Med-spa audits indicate approximately 70% volume retention at month 9, tapering to 40% by month 12, at which point most clients request a 0.3–0.5 mL refresher. E-BRID’s dense cross-link lattice slows enzymatic degradation, yet maintains enough porosity to encourage gradual isovolemic integration—water uptake replaces HA mass to keep contours stable as polymer chains shorten. Lifestyle factors matter: high-intensity exercise and smoking accelerate hyaluronidase activity, while antioxidant-rich diets appear to modestly extend persistence according to recent meta-analyses. MRI follow-ups reveal no particle migration beyond 2 mm from the injection plane, underscoring the gel’s cohesivity even in high-mobility zones like the oral commissure.

Q1 – Is Perfectha Derm FDA-approved?
A1: Not yet; the filler holds a CE mark for Europe but lacks FDA clearance in the United States.

Q2 – How quickly will I see results?
A2: Improvements are visible immediately. Minor swelling resolves within 24–48 hours, unveiling the final contour.

Q3 – Can the filler be dissolved?
A3: Yes. Like all HA gels, Perfectha Derm responds to hyaluronidase; most over-corrections flatten within minutes.

Perfectha Derm is manufactured by Sinclair, a UK-based aesthetics company founded in 1971 and now operating in 55 countries through direct affiliates and distributors. Sinclair’s French production site holds ISO 13485 certification, and every Perfectha batch undergoes sterility, particulate and endotoxin testing that exceed EU Pharmacopeia limits. The company’s innovation pipeline centres on collagen-stimulating and HA technologies—Perfectha sits alongside MaiLi and Ellansé within its holistic aesthetics portfolio. In 2018 Sinclair joined Huadong Medicine, bolstering global distribution and R&D funding for greener manufacturing. Environmental stewardship is evolving: the 2024 Corporate Responsibility update pledges 100% renewable electricity for EU plants by 2030 and a 40% reduction in plastic secondary packaging. Socially, the firm funds annual injector scholarships and supports Women in STEM initiatives across Europe and LATAM. Taken together, Sinclair’s century-spanning heritage, stringent quality systems and forward-looking sustainability goals reinforce Perfectha Derm’s reputation as a safe, effective and ethically produced solution for mid-depth wrinkle correction.